Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D. James, Mahesh Parmar|The Lancet|2015Cited by 2k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet|2019Cited by 223
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam‐Hogan, R. Steele, John Bridgewater et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 64
Assessing Whether to Perform a Confirmatory Randomized Clinical TrialMahesh Parmar, Richard H. Simon, Richard S. Ungerleider|JNCI Journal of the National Cancer Institute|1996Cited by 59
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet Oncology|2022Cited by 45